^
Association details:
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Title:

Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

Excerpt:
Summary of recommendations...Ewing Sarcoma...ChT regimens in relapse situations are not standardised and include alkylating agents (cyclophosphamide and high-dose ifosfamide) in combination with topoisomerase inhibitors (etoposide and topotecan), irinotecan with temozolomide [III, B] or gemcitabine and docetaxel, or high-dose ifosfamide or carboplatin with etoposide.
DOI:
10.1093/annonc/mdy310